Last reviewed · How we verify
A Phase 1 Study of AFP Specific T Cell Receptor Transduced T Cells Injection in Unresectable Hepatocellular Carcinoma
A phase 1 study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients.
Details
| Lead sponsor | Shanghai AbelZeta Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | UNKNOWN |
| Enrolment | 9 |
| Start date | 2019-08-06 |
| Completion | 2021-04 |
Conditions
- Hepatocellular Carcinoma
Interventions
- AFP Specific T Cell Receptor T Cells
Primary outcomes
- Incidence of treatment related adverse events as assessed by CTCAE v4.0[Safety of C-TCR055] — start treatment to 12 months
Determine if treatment with C-TCR055 is safe through assessment of adverse events(AEs) and serious adverse events(SAEs) as assessed by CTCAE v4.0
Countries
China